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Four other keywords to critically analyze a clinical trial:
hypothesis, implementation, analysis and publication
Otras cuatro palabras clave para analizar críticamente un ensayo 
clínico: hipótesis, realización, análisis y publicación
I believe that Ugalde and Homedes (1)
analyze correctly the false arguments used by the
pharmaceutical industry to disguise its business
as science in Latin America and I believe that the
examples they provide clearly put into context
the pressing matter of the lack of transparency. 
In my contribution, I intend to extend
the analysis of Ugalde and Homedes in order to
include other aspects that I consider fundamental
to a critical analysis of clinical trials, regardless of
the geographical location in which they are
conducted. My exposition is organized according
to four keywords corresponding to the phases
every clinical trial must go through: statement of
the study hypothesis, establishment of the
protocol and implementation of the study, anal-
ysis of the data collected and, finally, publication
of the results. I will now highlight the irregular-
ities and crimes that arise in each of these phases.
1. Statement of the study hypothesis
Back in 1993 Dr. Ian Hay’s virology
laboratory in the US, where I conducted my first
research studies, analyzed the possible relation
between Chronic Fatigue Syndrome and the
Herpes simplex virus type 6 and 7. When I asked
Dr. Hay how the research objectives were
defined in his laboratory, he invited me into his
office and explained the following: in the US,
biomedical research is mainly funded by the
National Institutes of Health (NIH); the NIH
establish their priorities according to a list given
to them by the United States Congress, whose
members (most of them millionaires) are
pressured by lobbies and generally yield to the
most powerful groups. That is to say, that the
priorities of medical research in the US are
related to political and economic interests that
have nothing to do with the real health interests
of the American population, much less of the
world population. Why is it that there are no
long-term studies comparing the health indicators
of vaccinated versus non-vaccinated children?
(2). Why has no double-blind study been done to
test the efficacy of the seasonal flu vaccine, as the
head of the area of flu vaccines in the Cochrane
Collaboration (Dr. Tom Jefferson) has been
requesting for over ten years? (3). Why is it that
study hypotheses are allowed that compare the
possible effect of a new drug that the industry
wants to release in the market with a placebo,
instead of hypotheses that compare the new drug
with the most effective drug that already exists? (4
p.221). Why do diseases affecting 90% of the
population only receive 10% of research re-
sources? (5 p.10).
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2. establishment of the protocol and
implementation of the study
After stating the study hypothesis, it is
time to establish the research protocol. There
may be mistakes in the writing of the protocol,
but I do not think they are usually intentional
abuses. However, I agree with Ugalde and
Homedes that the ethics committees that approve
the protocols are not usually capable of checking
whether the protocols are duly applied,
especially with regards to obtaining informed
consent. Frequently, the people that sign the
consent forms do not understand the con-
sequences and the context of what they are
signing. They often believe that if they do not
sign they will lose the right to be treated.
Regarding the abuse implied in using someone
for research purposes and then interrupting their
treatment once we have obtained from this
person the information we needed, I refer to the
article of Ugalde and Homedes (1). 
3. analysis of the data collected
The analysis of data is again a key point
in which abuses are committed that demonstrate
how profits are put before science. The most
frequent abuse, for which the majority of large
pharmaceutical companies in the US have
repeatedly been convicted, is that of concealing
information (6). The case of the association
between vioxx (rofecoxib) and myocardial
infarction (7 p.143) is widely known, as is that of
Hormone Replacement Therapy (HRT) and breast
cancer (8). More than 14,000 women sued the
pharmaceutical company Wyeth (taken over by
Pfizer in 2009) for concealing information related
to the risks of HRT with Prempo (conjugated
equine estrogens and medroxyprogesterone
acetate). The majority of the lawsuits are being
decided in favor of the plaintiffs and the judicial
process has already made public more than
1,500 documents evidencing the existence of
criminal responsibility. These documents have
not only revealed the crime of concealing
information but have also made known the full
scope of the issue I touch upon in the last section. 
4. Publication of the results
In terms of publication, 87% of the
authors of scientific articles have direct financial
ties to the industries that commercialize the drugs
the authors investigate. And, what is even worse,
most of the scientific articles currently published
in the most prestigious peer-reviewed medical
journals are not written by the people that stamp
their names on them; rather, their authors are
ghostwriters employed by specialized firms hired
by the pharmaceutical companies in order to
promote their products. Is it possible that the
most prestigious journals lend themselves to such
manipulation? This unbelievable situation is
precisely what Dr. Marcia Angell, editor in chief
for more than seventeen years of a medical
journal with one the highest impact factors (The
New England Journal of Medicine), denounced;
and it is the same situation that Georgetown
University researcher Adriane Fugh-Berman
denounces after analyzing the 1,500 documents
declassified during the trial against Wyeth/Pfizer
(9). Companies exist that specialize in disguising
propaganda as science, calling their work
"publication planning”; in their offer of services
they include both reviews and original articles.
During the eight years it was contracted by
Wyeth to promote HRT (between 1996 and
2004), a company called DesignWrite produced
more than a thousand abstracts and posters and
more than five hundred peer-reviewed articles,
established more than two hundred scientific
committees, organized more than ten thousand
conferences, more than two hundred satellite
symposiums, and more than sixty international
training programs, and created dozens of
webpages (9). To summarize the situation re-
garding clinical trials: the pharmaceutical
company first defines the study hypothesis
according to its private interests; next, it conducts
the study convinced that the irregularities
committed will have no consequences, because
there is no adequate control of the protocol
implementation; it then conceals any unfavorable
information; and finally, it contacts a physician of
good academic reputation to be the “main
author” of an article that has already been written
by an employee of the marketing company. The
existence of this situation was already known, but
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before the Wyeth case was studied, the magnitude
of the problem was not thought to be so large. 
the solution is within our reach
It is necessary to follow the suggestions
made by the health committee of the english
Parliament in the year 2005: that the public
health system acquire the capacity to carry out
its own studies of drug efficacy and safety,
independently of the companies that commer-
cialize such drugs and of their interests (10
p.116, recommendations 18-20). These re-
commendations have not as of yet spurred any
new laws or regulations. Currently, in england
as in the rest of the european countries, not only
do the studies of efficacy and safety remain in
the hands of the companies that commercialize
the drugs and that have been accused and
sentenced on numerous occasions for betraying
the trust placed in them, but the office that
grants licenses to commercialize drugs – the
european Medicines Agency (eMA) – receives
more than 50% of its funding from these same
companies. 
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